182 related articles for article (PubMed ID: 32449142)
1. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
Ogasawara K; Smith WB; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1109-1117. PubMed ID: 32449142
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
Zhang M; Xu C; Ma L; Shamiyeh E; Yin J; von Moltke LL; Smith WB
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):315-21. PubMed ID: 27136912
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
Ogasawara K; Vince B; Xu C; Zhang M; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 May; 85(5):995-1001. PubMed ID: 32318809
[TBL] [Abstract][Full Text] [Related]
4. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Ogasawara K; Xu C; Kanamaluru V; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 May; 85(5):899-906. PubMed ID: 32248324
[TBL] [Abstract][Full Text] [Related]
5. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
[TBL] [Abstract][Full Text] [Related]
6. Excretion balance and pharmacokinetics following a single oral dose of [
Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Ogasawara K; Zhou S; Krishna G; Palmisano M; Li Y
Cancer Chemother Pharmacol; 2019 Oct; 84(4):891-898. PubMed ID: 31444617
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.
Zhang M; Xu CR; Shamiyeh E; Liu F; Yin JY; von Moltke LL; Smith WB
J Clin Pharmacol; 2014 Apr; 54(4):415-21. PubMed ID: 24165976
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
Shimasaki Y; Sakaki M; Itou M; Kobayashi T; Aso M; Kagawa T; Saiki T; Matsuno K; Sano Y; Shimizu K; Kuroda S; Koumura E
Clin Drug Investig; 2018 Nov; 38(11):1041-1051. PubMed ID: 30194585
[TBL] [Abstract][Full Text] [Related]
10. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y; Ogasawara K; Wood-Horrall R; Thomas M; Thomas M; He B; Liu L; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2022 Oct; 90(4):325-334. PubMed ID: 36001108
[TBL] [Abstract][Full Text] [Related]
14. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
[TBL] [Abstract][Full Text] [Related]
16. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.
Pardanani A; Tefferi A; Jamieson C; Gabrail NY; Lebedinsky C; Gao G; Liu F; Xu C; Cao H; Talpaz M
Blood Cancer J; 2015 Aug; 5(8):e335. PubMed ID: 26252788
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
[TBL] [Abstract][Full Text] [Related]
20. Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
Li J; Chen J; Kanamaluru V; Gaemers SJM; Peterschmitt MJ; Hou AW; Xue Y; Turpault S; Rudin D
Mol Genet Metab; 2020 Feb; 129(2):117-124. PubMed ID: 31924461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
